Hinova Pharmaceuticals Inc. A - Asset Resilience Ratio
Hinova Pharmaceuticals Inc. A (688302) has an Asset Resilience Ratio of 15.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688302 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Hinova Pharmaceuticals Inc. A's Asset Resilience Ratio has changed over time. See Hinova Pharmaceuticals Inc. A (688302) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hinova Pharmaceuticals Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Hinova Pharmaceuticals Inc. A.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥220.52 Million | 15.84% |
| Total Liquid Assets | CN¥220.52 Million | 15.84% |
Asset Resilience Insights
- Good Liquidity Position: Hinova Pharmaceuticals Inc. A maintains a healthy 15.84% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hinova Pharmaceuticals Inc. A Industry Peers by Asset Resilience Ratio
Compare Hinova Pharmaceuticals Inc. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Hinova Pharmaceuticals Inc. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Hinova Pharmaceuticals Inc. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.46% | CN¥210.49 Million ≈ $30.80 Million |
CN¥1.36 Billion ≈ $199.24 Million |
-4.03pp |
| 2023-12-31 | 19.48% | CN¥290.62 Million ≈ $42.53 Million |
CN¥1.49 Billion ≈ $218.26 Million |
-1.62pp |
| 2022-12-31 | 21.11% | CN¥366.24 Million ≈ $53.59 Million |
CN¥1.74 Billion ≈ $253.90 Million |
+13.28pp |
| 2019-12-31 | 7.83% | CN¥3.50 Million ≈ $512.16K |
CN¥44.72 Million ≈ $6.54 Million |
-- |
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more